Spontaneous Loss of Surface Antigen Among Adults Living with Chronic Hepatitis B Virus Infection: a Systematic Review and Pooled Meta-analyses

Overview

Journal Lancet Gastroenterol Hepatol

Specialty Gastroenterology

Date 2019 Jan 26

PMID 30679109

Citations 38

Authors

Kali Zhou

Caitlin Contag

Evans Whitaker

Norah Terrault

Affiliations

Soon will be listed here.

Abstract

Background: Spontaneous loss of HBsAg (known as functional cure) in patients with chronic hepatitis B virus (HBV) infection significantly reduces liver-related complications. HBsAg loss has been suggested to be higher in non-endemic regions than in endemic regions in individual studies. We systematically determined a pooled annual rate of HBsAg loss in adults with untreated chronic HBV infection and examined the effect of regional endemicity.

Methods: In this systematic review and meta-analysis, we searched PubMed and Embase for observational cohort studies and non-treatment arms of randomised controlled trials reporting proportions of patients with chronic HBV infection that achieved spontaneous HBsAg loss, published up to Oct 1, 2018. We excluded randomised controlled trials from meta-analyses because of substantial cohort differences. Two reviewers (KZ and CC) independently extracted data from accepted full-text studies, with discrepancies discussed with a third reviewer (NT). We assessed rate of HBsAg loss, and stratified results by whether the underlying cohort arose primarily from an endemic region (defined as having prevalence of chronic HBV greater than 2%) or non-endemic region. This study is registered with PROSPERO, number CRD42018074086.

Findings: Of 5186 studies screened, 67 (11 randomised controlled trials, 39 prospective and 17 retrospective cohort studies) met the inclusion criteria and 56 were included in meta-analyses after exclusion of randomised controlled trials. Spontaneous HBsAg loss occurred in 3837 (7·8%) of 48 972 patients, with cumulative 352 381 person-years of follow-up. The pooled annual incidence of HBsAg loss was 1·17% (95% CI 0·94-1·41, I=97%). Rates did not differ by endemicity: 1·19% (0·88-1·54) in endemic versus 1·29% (0·99-1·62) in non-endemic cohorts.

Interpretation: Globally, spontaneous HBsAg loss occurs infrequently (about 1% per year) in treatment-naive adults with chronic HBV infection. The low and homogeneous rate of HBsAg loss highlights the need for new therapeutics aimed at achieving functional cure across different patient groups and geographical regions.

Funding: NIH National Institute of Diabetes and Digestive and Kidney Diseases.

Citing Articles

Baseline HBsAg quantitative and CD4 T cell counts are associated with HBsAg loss in people living with HIV/HBV coinfection after combined antiretroviral therapy.

Xia M, Zhao Y, Yu T, Lin X, Liao G, Jiang Y Front Cell Infect Microbiol. 2025; 15:1381826.

PMID: 40046188 PMC: 11880231. DOI: 10.3389/fcimb.2025.1381826.

Long-Term Outcome of Chronic Hepatitis B-Histological Score and Viral Genotype Are Important Predictors of Hepatocellular Carcinoma.

Eilard A, Ringlander J, Andersson M, Nilsson S, Norkrans G, Lindh M J Viral Hepat. 2025; 32(3):e70008.

PMID: 39878776 PMC: 11777188. DOI: 10.1111/jvh.70008.

Exploring using HBsAg to predict interferon treatment course to achieve clinical cure in chronic hepatitis B patients: a clinical study.

Yan F, Tang F, Chen J, Lin Y, Chen X, Du Q Front Immunol. 2025; 15:1528758.

PMID: 39867915 PMC: 11758162. DOI: 10.3389/fimmu.2024.1528758.

Hepatocellular carcinoma in HBsAg seroclearance: clinical features, recurrence, and prognosis following curative hepatectomy.

Xu W, Gong H, Li B, Yin X Ther Adv Med Oncol. 2024; 16:17588359241289202.

PMID: 39483138 PMC: 11526261. DOI: 10.1177/17588359241289202.

A high functional cure rate was induced by pegylated interferon alpha-2b treatment in postpartum hepatitis B e antigen-negative women with chronic hepatitis B virus infection: an exploratory study.

Zhong W, Yan L, Zhu Y, Shi L, He Y, Chen T Front Cell Infect Microbiol. 2024; 14:1426960.

PMID: 39176265 PMC: 11338904. DOI: 10.3389/fcimb.2024.1426960.

References

Yuen M, Wong D, Fung J, Ip P, But D, Hung I . HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology. 2008; 135(4):1192-9. DOI: 10.1053/j.gastro.2008.07.008. View

Arai M, Togo S, Kanda T, Fujiwara K, Imazeki F, Yokosuka O . Quantification of hepatitis B surface antigen can help predict spontaneous hepatitis B surface antigen seroclearance. Eur J Gastroenterol Hepatol. 2012; 24(4):414-8. DOI: 10.1097/MEG.0b013e328350594d. View

Tseng T, Liu C, Chen C, Yang W, Yang H, Su T . Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection. Aliment Pharmacol Ther. 2015; 41(10):949-60. DOI: 10.1111/apt.13170. View

Tsai P, Chang C, Chen K, Chang K, Hung S, Wang J . Acquirement and disappearance of HBsAg and anti-HCV in an aged population: a follow-up study in an endemic township. Liver Int. 2010; 31(7):971-9. DOI: 10.1111/j.1478-3231.2010.02363.x. View

Liaw Y, Sheen I, Chen T, Chu C, PAO C . Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology. 1991; 13(4):627-31. View

Sunbul M . Hepatitis B virus genotypes: global distribution and clinical importance. World J Gastroenterol. 2014; 20(18):5427-34. PMC: 4017058. DOI: 10.3748/wjg.v20.i18.5427. View

Chen Y, Liaw Y . Spontaneous HBsAg seroclearance confers excellent prognosis except in patients with cirrhosis. Hepatology. 2004; 40(2):501. DOI: 10.1002/hep.20378. View

Schweitzer A, Horn J, Mikolajczyk R, Krause G, Ott J . Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015; 386(10003):1546-55. DOI: 10.1016/S0140-6736(15)61412-X. View

de Franchis R, Meucci G, Vecchi M, Tatarella M, Colombo M, Del Ninno E . The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med. 1993; 118(3):191-4. DOI: 10.7326/0003-4819-118-3-199302010-00006. View

10.

Sanchez-Tapias J, Costa J, Mas A, Bruguera M, Rodes J . Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology. 2002; 123(6):1848-56. DOI: 10.1053/gast.2002.37041. View

11.

Martinot-Peignoux M, Boyer N, Colombat M, Akremi R, Pham B, Ollivier S . Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol. 2002; 36(4):543-6. DOI: 10.1016/s0168-8278(02)00004-1. View

12.

Zhang S, Chen Z, Jiang K, Wu W, Zhang C, Gu Y . Effect of seasonal variation on the clinical course of chronic hepatitis B. J Gastroenterol. 2006; 41(11):1107-15. DOI: 10.1007/s00535-006-1903-1. View

13.

Ungtrakul T, Sriprayoon T, Kusuman P, Chunnuan P, Soonklang K, Sornsamdang G . Role of quantitative hepatitis B surface antigen in predicting inactive carriers and HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients. Medicine (Baltimore). 2017; 96(13):e6554. PMC: 5380303. DOI: 10.1097/MD.0000000000006554. View

14.

Lauret E, Gonzalez-Dieguez M, Rodriguez M, Gonzalez M, Melon S, Rodrigo L . Long-term outcome in Caucasian patients with chronic hepatitis B virus infection after HBsAg seroclearance. Liver Int. 2014; 35(1):140-7. DOI: 10.1111/liv.12461. View

15.

Da Silva L, Madruga C, Carrilho F, Pinho J, Santos C, Bassit L . Spontaneous hepatitis B surface antigen clearance in a long-term follow-up study of patients with chronic type B hepatitis. Lack of correlation with hepatitis C and D virus superinfection. J Gastroenterol. 1996; 31(5):696-701. DOI: 10.1007/BF02347619. View

16.

Kobayashi M, Hosaka T, Suzuki F, Akuta N, Sezaki H, Suzuki Y . Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up. J Gastroenterol. 2013; 49(3):538-46. DOI: 10.1007/s00535-013-0821-2. View

17.

Chen Y, Chu C, Liaw Y . Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology. 2009; 51(2):435-44. DOI: 10.1002/hep.23348. View

18.

Niederau C, Amani A, Thiel A . Long-term follow-up of HBsAg-positive patients in Germany. Eur J Gastroenterol Hepatol. 2015; 28(1):48-56. DOI: 10.1097/MEG.0000000000000487. View

19.

Cunha-Silva M, Marinho F, Oliveira P, Lopes T, Seva-Pereira T, Lorena S . Retrospective analysis of hepatitis B virus chronic infection in 247 patients: clinical stages, response to treatment and poor prognostic factors. Braz J Infect Dis. 2017; 21(4):441-447. PMC: 9428035. DOI: 10.1016/j.bjid.2017.03.019. View

20.

Dienstag J, Schiff E, Wright T, Perrillo R, Hann H, Goodman Z . Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999; 341(17):1256-63. DOI: 10.1056/NEJM199910213411702. View